New pill combo aims to tame advanced prostate cancer
NCT ID NCT06568094
First seen Nov 18, 2025 · Last updated May 25, 2026 · Updated 25 times
Summary
This study tests a new pill called HRS-5041 combined with other cancer treatments for men with advanced prostate cancer that has spread or stopped responding to standard therapy. About 100 men aged 18-80 will participate to find the best dose and see if the combo can shrink tumors or lower PSA levels. The goal is to control the disease and improve survival, not to cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Jiao Tong University School of Medicine, Renji Hospital
RECRUITINGShanghai, Shanghai Municipality, 200433, China
Contact
-
The Second Affiliated Hospital of Harbin Medical University
RECRUITINGHarbin, Heilongjiang, 150000, China
Contact
Conditions
Explore the condition pages connected to this study.